Extra-gastrointestinal stromal tumors (EGISTs): A case report for a mischief entity

dc.contributor.authorEl Charif, Mohamad Hadi
dc.contributor.authorAmro, Sara
dc.contributor.authorBoulos, Fouad I.
dc.contributor.authorKhalife, Mohamad Jawad
dc.contributor.authorShamseddine, Ali I.
dc.contributor.authorAssi, Hazem I.
dc.contributor.authorSbaity, Eman
dc.contributor.departmentInternal Medicine
dc.contributor.departmentSurgery
dc.contributor.departmentPathology and Laboratory Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:45:13Z
dc.date.available2025-01-24T11:45:13Z
dc.date.issued2023
dc.description.abstractBackground: Extra-gastrointestinal stromal tumor is a rare subtype of soft tissue sarcomas with significantly variable presentation, management, and prognosis. This makes it crucial to report the different institutional experiences of encountering extra-gastrointestinal stromal tumors (EGIST). Case presentation: We report 3 cases of EGIST diagnosis at American University of Beirut Medical Center for 2 males and 1 female in the 5th, 6th, and 7th decades of life, respectively. For the first case, the tumor was initially suspected to be ovarian cancer, but biopsy revealed a diagnosis of EGIST, and the patient was started on neoadjuvant therapy. In the second case, the tumor was retro-gastric and prelim diagnosis was gastric cancer but again biopsy revealed an EGIST histopathology, and the patient underwent surgery and adjuvant treatment. For the third case, a previous history of testicular cancer prompted an initial suspicion of recurrence with metastasis but biopsy and immunohistochemistry staining revealed EGIST with related markers. The patient underwent treatment at a different institution in his home country. Conclusion: This report sheds light on the importance of keeping EGIST amongst any differential list for abdominal and pelvic tumors. It also shows that EGIST-focused studies are needed to assess the effectiveness of the different treatment modalities available when utilized specifically for EGIST. This would allow for better oncological outcomes and improved quality of life. © 2023 Lippincott Williams and Wilkins. All rights reserved.
dc.identifier.doihttps://doi.org/10.1097/MD.0000000000033394
dc.identifier.eid2-s2.0-85151575304
dc.identifier.pmid37000068
dc.identifier.urihttp://hdl.handle.net/10938/30541
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofMedicine (United States)
dc.sourceScopus
dc.subjectCase report
dc.subjectEgist
dc.subjectExtra-gastrointestinal stromal tumor
dc.subjectHistology
dc.subjectSoft tissue sarcoma
dc.subjectSubtype
dc.subjectFemale
dc.subjectGastrointestinal stromal tumors
dc.subjectHumans
dc.subjectMale
dc.subjectPelvic neoplasms
dc.subjectPrognosis
dc.subjectQuality of life
dc.subjectTesticular neoplasms
dc.subjectImatinib
dc.subjectAdjuvant therapy
dc.subjectAdult
dc.subjectAged
dc.subjectArticle
dc.subjectCancer adjuvant therapy
dc.subjectCancer diagnosis
dc.subjectCancer growth
dc.subjectCancer recurrence
dc.subjectCancer surgery
dc.subjectClinical article
dc.subjectDisease exacerbation
dc.subjectFollow up
dc.subjectGastrointestinal stromal tumor
dc.subjectHistopathology
dc.subjectHuman
dc.subjectHuman tissue
dc.subjectImmunohistochemistry
dc.subjectMedical history
dc.subjectMedical record review
dc.subjectMiddle aged
dc.subjectNausea
dc.subjectNeoadjuvant therapy
dc.subjectOvary cancer
dc.subjectPartial gastrectomy
dc.subjectPeritoneum metastasis
dc.subjectPositron emission tomography
dc.subjectStomach cancer
dc.subjectTestis cancer
dc.subjectTumor biopsy
dc.subjectX-ray computed tomography
dc.subjectPathology
dc.subjectPelvis tumor
dc.subjectTestis tumor
dc.titleExtra-gastrointestinal stromal tumors (EGISTs): A case report for a mischief entity
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023-822.pdf
Size:
672.48 KB
Format:
Adobe Portable Document Format